Ayala Pharmaceuticals Inc (AYLA)


Stock Price Forecast

Jan. 19, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ayala Pharmaceuticals Inc chart...

About the Company

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE).

Exchange

NASDAQ

Website

www.ayalapharma.com

$1M

Total Revenue

35

Employees

$7M

Market Capitalization

-0.46

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AYLA News

IMNM Oct 2024 25.000 put

2d ago, source: Yahoo Finance

BOTHELL, Wash., February 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the ...

2024's 10 Best-Performing Stocks

on MSN ago, source:

Top 2024 stock market performers include health care stocks with unique catalysts, artificial intelligence stocks and a stock tied to former President Donald Trump. Here are the 10 best-performing ...

J&J Adds to 2024 M&A Upswing

13d ago, source: BioSpace

Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.

"As sportsmen, we live on painkillers...pharmaceuticals have played role in terms of recovery": Javagal Srinath

2d ago, source: Asian News International on MSN

Former India seamer Javagal Srinath has said that pharmaceuticals and multivitamins have played a role in terms of recovery ...

Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)

5d ago, source: Business Insider

Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals. Currently, the analyst consensus on ...

EyePoint Pharmaceuticals: Q4 Earnings Snapshot

11d ago, source:

WATERTOWN, Mass. (AP) — WATERTOWN, Mass. (AP) — EyePoint Pharmaceuticals (EYPT) on Thursday reported a loss of $14.1 million in its fourth quarter. On a per-share basis, the Watertown, ...

IMNM Oct 2024 25.000 call

2d ago, source: Yahoo Finance

BOTHELL, Wash., February 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...